Ekf Diagnostics Share Discussion Threads

[tongosti] 28/11/2020 09:57

Thought (big ask for you dear pal Joe) for the weekend: EKF is down about -24% since 9th of Nov (the Pfizer vaccine news day). FTSE All Share is +7.3% during the same period. There is a -31% relative underperformance. Those who have ever bothered (granted - they are not to be found in this FanClub) to crunch the numbers on near term relative strength signals would be far more cautious than the usual broken records who think are far smarter than the market.

[tongosti] 28/11/2020 09:28

Have a look around these boards and see how many Joes like yourself have been outsmarted by yours truly. Patience sport patience. PS. Happy seeing a few crowd member/ been following an alternative approach. Who says they don't get anything?!

[chris16041] 28/11/2020 08:36

Don`t normally post on these boards too many rampers and derampers This chap tongosi aka Mr Market appears to have set himself up as an expert In truth he is not very good. I happened to come across him on the Sfor board proudly announce he was opening a short.The shares went up almost 3% yesterday much to my delight Tongosti verses Sir Martin Sorrell no contest. I strongly advise you to close your short old boy before Mr Market does more damage to your wealth Toodle Pip

[tongosti] 27/11/2020 16:03

Glad seeing you're following me closely sport - I wonder why is that. Re sfor - opened up today so one needs to give the trade a few days or so. If it doesn't work, my stop is designed to bail me out at 2% of my account level. I am in control of risk - always and without fail. Mr Market is only in charge of gifts. Beat that Einstein!

[retirementfund] 27/11/2020 15:37

How's your Sfor short going Tongosti you must be desperate rocking up on here your negative isn't correlating with their rising share price enjoy. As for EKF I worry for you with what is likely coming next week

[tongosti] 27/11/2020 15:26

The number of bullish posts has been perfectly negatively correlated with the share price action since that now distant 82 level. Mr Market must love all this.

[wan] 27/11/2020 13:14

Here is another thought for the day. EKF have already confirmed they intend to maintain a dividend policy. So, if we assume that the dividend will be the same, or greater than the current 1p dividend per share, what value might we also factor in for the potential in-specie dividend for Trellus Health? With the main thrust being, what the prospective dividend yield might be in relation to the current share price. Even if you want to be conservative and assume the total dividend (including Trellus Health) as amounting to only 2p, that gives a prospective yield of over 3% (based on the current mid price). Of course this does not then account for the growth on offer from a successful IPO of Trellus, and subsequently the direct exposure to the digital health opportunity, which is experiencing rapid rates of growth, increased investor interest, and attracting increasing amounts of corporate activity.

[wan] 27/11/2020 09:07

Wilmdav...The IDS card test looks like an unbranded Abbott BionaxNow. The unbranded cassette could be anybody's given the similarities they all have. Anyway, apart from the share price reaction highlighting the potential exposure to the rapid expansion in testing that's currently taking place, I cannot see any EKF connection with those particular devices. Hopefully though, EKF may yet benefit from the rapid expansion in antigen testing too via ATM (as well as extraction-less testing), and ultimately the fact that antigen testing results in confirmatory PCR tests.

[wan] 27/11/2020 08:49

edit to my post above - but overall the negative effects on testing revenues are probably not as much as the market currently assumes.

[btgman] 27/11/2020 08:43

Great post Wan I have exactly the same view the market has the exact reverse thought process as to what is actually happening regards testing. EKF are playing a cautious approach around upgrades and waiting to see everything come through and in place before they announce which I totally support. If this is correct the share price will appreciate rapidly between now and the trading update in early Jan. AIMHO GLA BTG

[wan] 27/11/2020 08:26

With vaccines on the horizon, probably like many others I have been challenging myself as to what level of Covid-19 testing will be required on initial and wider roll out of vaccines. There is no doubt in my mind that testing is currently going in the opposite direction to what the market currently appears to think, albeit I appreciate the market is looking beyond the here and now (and thereby may be underestimating the current growth/expansion in testing). A thought that has been going through my mind, is what if you develop symptoms even if you have received the vaccine? Then obviously you will still need to be tested to decipher whether it's flu or Covid-19, or indeed something else such as a mutation. In short, if you are symptomatic, having received a vaccine or not, you will still need to be tested, which will almost certainly be via a PCR test. Back to the current testing expansion. By now everyone is aware of the current expansion of antigen testing, and indeed imminent acceleration in the expansion of antigen testing. The following, demonstrates how antigen testing, will result in a PCR test i.e. a sample being sent to the lab - New Covid-19 asymptomatic testing site starts at the University of Birmingham 26 Nov 2020 Government-backed asymptomatic testing site to open at the University of Birmingham to help protect people most at risk . Students will be encouraged to get tested during the first week of December using Lateral Flow Devices. If they receive a negative test, they are advised to return home immediately. Should a student test positive they will then need to book a confirmatory PCR and have to self-isolate for 10 days, still with enough time to return home for Christmas. hTTps://www.birmingham.ac.uk/news/latest/2020/11/new-covid-19-asymptomatic-testing-site-starts-at-the-university-of-birmingham.aspx Back to vaccines. In combination with the PCR test scenario's I highlight above, antibody testing will go hand-in-hand with any vaccine roll-out, for testing the effectiveness post-vaccination and testing to learn how long immunity lasts. In short, antibody testing is likely to see a dramatic increase in demand. So, to my mind a key consideration with EKF is, to what degree PCR testing reduces, in comparison to now, and to what degree the antibody testing demand will have, compared to 'nothing' now. Again, we can only guess, but overall the negative effects on testing revenues are probably not as much as the market currently assumes. Factor in that any vaccine roll-out will assist a further rebound in the core business, then it's probably why the CEO remarked as he did regarding the share price reaction. Not to mention the prospects for Trellus Health (and any other partnership opportunities).

[wilmdav] 27/11/2020 08:19

wan As I write Immunodiagnostic Systems (IDH) is up 32% on the this morning's announcement re launch of rapid antigen tests. Would you be willing to take a look at it to see if it might have any relevance to EKF Https://www.investegate.co.uk/immunodiagnostic-sys--idh-/rns/launch-of-sars-cov-2-antigen-rapid-tests/202011270700016864G/ Https://www.idsplc.com/covid-19-immunoassays/

[btgman] 27/11/2020 07:27

Is anyone else thinking we may see another trading update next week. Personally I think it is highly likely we will se further upgrades to current guidance AIMHO GLA BTG

[pldazzle] 26/11/2020 20:17

?? I don't have a problem with the numbers. 1.675m shares @£4.60 = £7.705m gross proceeds which is what was announced. The profit of "over £5.6m" is £7.705m, less costs of sale, less the original cost; that looks reasonable enough to me.

[chris16041] 26/11/2020 20:05

I am a tad puzzled at the sales figures produced for the recent share sale The difference between the gross and net figures quoted appears significant and i find it difficult to accept this difference can be explained as dealing costs Am I missing something here

[tongosti] 26/11/2020 16:56

Does our Joe deserve a reply when he has been using foul language recently? No - he doesn't. Only thing I will tell him is that during bull markets our dear pal Joe confuses luck with brains...

[mg1982] 26/11/2020 16:48

tong, I'm sure all of us are curious to know this, how old are you? I'm guessing by the type of messages you put on various BB's that you can't be older than 20? Grow up.

[tongosti] 26/11/2020 16:42

One of the timeless pieces of wisdom in this business: watch out when it's all blue sky and Mr Market stops responding. Another one: markets top on good news. Always and without fail. The reverse is true at market bottoms. Buona fortuna

[btgman] 26/11/2020 15:25

Market reaction about right for the profits raised on Renalytix disposal look about right. Reaction to new testing kit is mooted but lets wait and see what the numbers this adds to profit. Market seems happy to ignore underlying upgrades but the results and next trading update should address this. absolute steel at current levels AIMHO GLA BTG

[wan] 26/11/2020 14:44

Now available on EKF's website, inquire now - Precise and reliable measurement of COVID-19 IgG antibodies The Kantaro COVID-SeroKlir kit is a direct ELISA for the quantitative detection of human IgG antibodies to the SARS-CoV-2 virus in serum and plasma (K2-EDTA/Li-Heparin) samples. COVID-SeroKlir is both FDA and CE-IVD cleared. The SeroKlir ELISA kit was developed by clinicians at the Icahn School of Medicine at Mount Sinai Health System, New York(1). The test has been trialled on a cohort of more than 70,000 patients including over 30,000 who were diagnosed with COVID-19(2). The SeroKlir ELISA kit contains components to test 630 patient samples and uses standard ELISA protocols and equipment. The test comprises a two-phase ELISA, the initial plate screens for RBD positive or negative samples and the second plate provides a quantitative result of the antibody titre (concentration) using full length Spike protein. Specificity 99.6% Sensitivity 97.8% hTTps://www.ekfdiagnostics.com/COVID-SeroKlir.html

[tongosti] 26/11/2020 14:15

Mr Market hardly excited isn't he?

[wan] 26/11/2020 09:56

Charlieej....Clearly it's quite a task/achievement to get authorisation on the 'scaled version' i.e. the results can be achieved routinely with a high degree of agreement across millions of tests per month (compared to relative low volume product). So, I think that's the reason for the tweak. As I said before, it potentially provides for a second wind in light of the increased interest from vaccine developers (for those starting out and those now no longer locked into phase 3 studies) and indeed to gain a much needed understanding of immunity generally. So, I am sticking with my view that demand is likely be very high.